Skip to main content
. 2021 Feb;12(1):174–183. doi: 10.21037/jgo-20-534

Figure 3.

Figure 3

Kaplan-Meier survival analysis of ALDOA for OS and RFS. (A) Survival analysis of ALDOA for OS in the TCGA-LIHC cohort. (B) Survival analysis of ALDOA for RFS in the TCGA-LIHC cohort. (C) Survival analysis of ALDOA for OS in the GSE14520 cohort. (D) Survival analysis of ALDOA for RFS in the GSE14520 cohort. (E) Survival analysis of ALDOA for OS based on TNM I+II stage in the TCGA-LIHC cohort. (F) Survival analysis of ALDOA for OS based on TNM III+IV stage in the TCGA-LIHC cohort. (G) Survival analysis of ALDOA for OS based on TNM I+II stage in the GSE14520 cohort. (H) Survival analysis of ALDOA for OS based on TNM III stage in the GSE14520 cohort. ALDOA, aldolase A; OS, overall survival; RFS, relapse-free survival; TCGA-LIHC, The Cancer Genome Atlas-Liver Hepatocellular Carcinoma; TNM, tumor, node, metastasis.